News & Updates
Filter by Specialty:
Upadacitinib provides robust, long-term control of moderate-to-severe AD
Follow-up data from two replicate ongoing phase III trials – Measure Up 1 and Measure Up 2 – demonstrated favourable longer-term benefit-risk profile of upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis (AD).
Upadacitinib provides robust, long-term control of moderate-to-severe AD
23 May 2022
Lirentelimab shows promise in treatment-resistant chronic urticaria
In patients who suffer from antihistamine-resistant chronic urticaria (CU), lirentelimab seems to be effective at controlling the disease and reducing disease activity, reports a recent study.
Lirentelimab shows promise in treatment-resistant chronic urticaria
14 May 2022
Depression, anxiety aggravated in vitiligo patients
Vitiligo patients suffer from greater levels of depression and anxiety, both of which appear to be associated with serum levels of corticotropin releasing hormone, reveals a recent study.
Depression, anxiety aggravated in vitiligo patients
14 May 2022
Chamomile improves skin recovery in breast cancer patients with radiodermatitis
A topical formulation containing chitosan-coated Chamomilla recutita (L.) rauschert microparticles does not lower any grade of radiodermatitis (RD) but is effective in reducing grade ≥2 toxicity to improve skin recovery and diminish high-intensity local symptoms in women with breast cancer, a study has shown.
Chamomile improves skin recovery in breast cancer patients with radiodermatitis
13 May 2022
SWOG S1616 suggests PFS benefit with ipi-nivo combo in metastatic/unresectable melanoma
The combination of ipilimumab and nivolumab may provide a progression-free survival (PFS) benefit in patients with metastatic or unresectable melanoma who did not respond to anti-PD-1/anti-PD-L1 therapy, according to a small study presented at AACR 2022.
